Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
CONCLUSIONS: Secukinumab and ustekinumab have similar sustained drug survival, whilst adalimumab has a lower drug survival in patients with psoriasis. Psoriatic arthritis and previous biologic experience were predictors with differential effects between the biologic therapies.
PMID: 32124442 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group Tags: Br J Dermatol Source Type: research
More News: Arthritis | Dermatology | Humira | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Stelara | Study | UK Health